纳曲酮-安非他酮与行为疗法单用及联用治疗暴食障碍:随机双盲安慰剂对照试验
该随机双盲安慰剂对照试验纳入136例暴食障碍合并肥胖患者,采用2×2析因设计比较纳曲酮-安非他酮与行为体重减轻疗法(BWL)单用及联用16周的效果。意向性分析显示暴食缓解率分别为安慰剂组17.7%、纳曲酮-安非他酮组31.3%、BWL+安慰剂组37.1%、BWL+纳曲酮-安非他酮组57.1%;BWL显著优于无BWL,药物显著优于安慰剂,但两者无显著交互作用。
要点
- BWL和纳曲酮-安非他酮均显著改善暴食缓解,BWL+药物组缓解率最高达57.1%。
- BWL在暴食频率、5%体重减轻及次要指标上均显著优于无BWL。
- 药物与BWL之间无显著交互作用,提示二者疗效相对独立。
核心结论
- BWL和纳曲酮-安非他酮均与暴食障碍的显著改善相关,且BWL一致优于无BWL。
研究设计与样本
- 随机双盲安慰剂对照试验,2×2析因设计,2017年2月至2021年2月纳入136例暴食障碍合并肥胖患者。
- 81.6%为女性,平均年龄46.5岁,平均BMI 37.1,随机分入16周安慰剂(N=34)、纳曲酮-安非他酮(N=32)、BWL+安慰剂(N=35)或BWL+纳曲酮-安非他酮(N=35)。
- 81.7%的参与者完成了独立治疗后评估。
主要发现
- 意向性分析暴食缓解率:安慰剂组17.7%,纳曲酮-安非他酮组31.3%,BWL+安慰剂组37.1%,BWL+纳曲酮-安非他酮组57.1%。
- 逻辑回归显示BWL显著优于无BWL,纳曲酮-安非他酮显著优于安慰剂,但BWL与药物间无显著交互作用。
- 达到5%体重减轻的比率:安慰剂组11.8%,纳曲酮-安非他酮组18.8%,BWL+安慰剂组31.4%,BWL+纳曲酮-安非他酮组38.2%。
- 混合模型显示BWL在暴食频率、进食障碍精神病理、抑郁、进食行为及胆固醇和HbA1c水平上均显著优于无BWL。
关键数值与推荐
- 暴食缓解率在BWL+纳曲酮-安非他酮组为57.1%,在安慰剂组为17.7%。
- 5%体重减轻率在BWL+纳曲酮-安非他酮组为38.2%,在安慰剂组为11.8%。
临床怎么用
- 对于暴食障碍合并肥胖患者,行为体重减轻疗法可作为核心干预,显著改善暴食及体重相关结局。
- 纳曲酮-安非他酮可作为药物治疗选择,与BWL联用可能获得最高的暴食缓解率。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Binge-eating disorder, the most prevalent eating disorder, is a serious public health problem associated with obesity, psychiatric and medical comorbidities, and functional impairments. Binge-eating disorder remains underrecognized and infrequently treated, and few evidence-based treatments exist. The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity. METHODS: In a randomized double-blind placebo-controlled trial conducted from February 2017 to February 2021, using a 2×2 balanced factorial design, 136 patients with binge-eating disorder (81.6% women; mean age, 46.5 years; mean BMI, 37.1) were randomized to one of four 16-week treatments: placebo (N=34), naltrexone-bupropion (N=32), BWL+placebo (N=35), or BWL+naltrexone-bupropion (N=35). Overall, 81.7% of participants completed independent posttreatment assessments. RESULTS: Intention-to-treat binge-eating remission rates were 17.7% in the placebo group, 31.3% in the naltrexone-bupropion group, 37.1% in the BWL+placebo group, and 57.1% in the BWL+naltrexone-bupropion group. Logistic regression of binge-eating remission revealed that BWL was significantly superior to no BWL, and that naltrexone-bupropion was significantly superior to placebo, but there was no significant interaction between BWL and medication. Mixed models of complementary measures of binge-eating frequency also indicated that BWL was significantly superior to no BWL. The rates of participants attaining 5% weight loss were 11.8% in the placebo group, 18.8% in the naltrexone-bupropion group, 31.4% in the BWL+placebo group, and 38.2% in the BWL+naltrexone-bupropion group. Logistic regression of 5% weight loss and mixed models of percent weight loss both revealed that BWL was significantly superior to no BWL. Mixed models revealed significantly greater improvements for BWL than no BWL on secondary measures (eating disorder psychopathology, depression, eating behaviors, and cholesterol and HbA1c levels). CONCLUSIONS: BWL and naltrexone-bupropion were associated with significant improvements in binge-eating disorder, with a consistent pattern of BWL being superior to no BWL.
引用
- Grilo CM, Lydecker JA, Fineberg SK, et al. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2022. PMID: 36285406. doi:10.1176/appi.ajp.20220267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。